The World Health Organization (WHO) has suspended Bharat Biotech’s Covaxin supplies via UN procurement agencies.
The Indian biotechnology company issues a clarification on the same. It highlights that there is “no impact on efficacy and safety of the COVID-19 vaccine COVAXIN“.
“For the millions who have received COVAXIN, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine,” says the statement.
WHO on Saturday suspended the supply of Covaxin under the Covax facility. The move comes after the UN agency pointed out deficiencies in manufacturing practices.
“The World Health Organization (WHO) is today confirming the suspension of supply of Covaxin produced by Bharat (Biotech), through UN procurement agencies and recommending to countries that received the vaccine to take actions as appropriate,” the UN agency statement reads.
Latest Tweet from Bharat Biotech
“As all existing facilities were repurposed for the manufacture of COVAXIN, with continuous production during the past year, to meet the public health emergency of COVID-19, these upgrades were due. Certain highly sophisticated equipment which was required to enhance the process stringency was unavailable during the COVID-19 pandemic. It has to be stressed that the quality of COVAXIN was never compromised at any point in time,” it adds.
The company reiterates that it is working for further improvements and upgrades.
The WHO also stresses that the risk assessment to date does not indicate a change in the risk-benefit ratio.
YOU MAY ALSO WATCH:
ALSO READ | Two Best Ways To Have ‘Super Immunity’ Against Coronavirus
